Literature DB >> 31229481

Optimization of Transbronchial Cryobiopsy in Lung Transplant Recipients.

Karina Loor1, Mario Culebras2, Irene Sansano3, Antonio Álvarez2, Cristina Berastegui2, Javier de Gracia4.   

Abstract

BACKGROUND: Previous studies suggest that transbronchial lung biopsy using a cryoprobe is superior to transbronchial lung biopsy using forceps for evaluating lung grafts, although the technique can be associated an increase in complications. Because cryoprobe experience is limited, assessment of a greater number of cases is warranted. This prospective study evaluates the diagnostic yield, complications, and risk factors associated with the cryoprobe technique.
METHODS: From April 2013 to April 2016, 321 consecutive cryoprobe transbronchial biopsies were indicated in single or bilateral lung transplant patients with acute or chronic clinical lung injury or in asymptomatic patients before hospital discharge after lung transplantation.
RESULTS: With a mean of 4.32 lung parenchyma specimens per procedure, adequate alveolar lung parenchyma was obtained in 96.6% (84.27 ± 44.14 mm2) of cases. Obtaining at least 4 samples increased the histological diagnostic certainty (P < .001). Moderate to severe bleeding was observed in 7.48% of patients and was significantly more frequent in patients with unilateral transplantation (odds ratio, 0.10; 95% confidence interval, 0.02-0.30; P < .001) and in those with high blood pressure during scanning (odds ratio, 0.31; 95% confidence interval, 0.12-0.86; P = .019). Pneumothorax was observed in 7.7% of the patients, but only 3.7% of these patients required pleural drainage.
CONCLUSIONS: Obtaining 4 or more cryobiopsy samples is valuable and safe for lung allograft monitoring. Being a recipient of a unilateral lung transplant or having arterial hypertension during bronchoscopy seem to be risk factors associated with increased bleeding.
Copyright © 2019 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31229481     DOI: 10.1016/j.athoracsur.2019.04.096

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  Donor-derived, cell-free DNA levels by next-generation targeted sequencing are elevated in allograft rejection after lung transplantation.

Authors:  Kiran K Khush; Iwijn De Vlaminck; Helen Luikart; David J Ross; Mark R Nicolls
Journal:  ERJ Open Res       Date:  2021-01-25

2.  Clinical Validation of a Plasma Donor-derived Cell-free DNA Assay to Detect Allograft Rejection and Injury in Lung Transplant.

Authors:  Justin P Rosenheck; David J Ross; Mena Botros; Alexander Wong; Jonathan Sternberg; Yen-An Chen; Nathan Liang; Amy Baer; Ebad Ahmed; Ryan Swenerton; Bernhard G Zimmermann; Gordon Fehringer; Zachary P Demko; Michael Olymbios; Paul R Billings; Brian C Keller
Journal:  Transplant Direct       Date:  2022-03-25

Review 3.  Surveillance for acute cellular rejection after lung transplantation.

Authors:  Mark Greer; Christopher Werlein; Danny Jonigk
Journal:  Ann Transl Med       Date:  2020-03

4.  Histological Findings in Transbronchial Cryobiopsies Obtained From Patients After COVID-19.

Authors:  Mario Culebras; Karina Loor; Irene Sansano; Óscar Persiva; David Clofent; Eva Polverino; Almudena Felipe; Jeisson Osorio; Xavier Muñoz; Antonio Álvarez
Journal:  Chest       Date:  2021-09-25       Impact factor: 9.410

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.